

PROPOSED AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings of claims, in the application:

LISTING OF CLAIMS:

Claim 1. (previously presented) An isolated mammalian anti-Dengue virus antibody, comprising at least one variable region comprising the amino acid sequence set forth in SEQ ID NO: 4.

Claim 2. (original) An antibody according to Claim 1, wherein said antibody binds Dengue virus NS-1 protein.

Claim 3. (original) An anti-Dengue virus antibody according to Claim 1, wherein said antibody binds at least one Dengue virus NS protein.

Claims 4-8. (canceled)

Claim 9. (previously presented) A composition comprising at least one isolated mammalian anti-Dengue virus antibody having at least one variable region comprising an amino acid sequence set forth in SEQ ID NO: 4, and at least one pharmaceutically acceptable carrier or diluent.

Claim 10. (previously presented) A composition according to Claim 9, further comprising at least one composition comprising a therapeutically or prophylactically effective amount of at least one compound or protein selected from the group consisting of a detectable label or reporter, a Dengue virus replication antagonist, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, an antimicrobial, a corticosteroid, an erythropoietin, an antigen for immunization, an immunoglobulin, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an asthma medication, an inhaled steroid, an epinephrine or analog, a cytokine, and a cytokine antagonist.

Claim 11. (withdrawn) A method for diagnosing or treating a Dengue virus-related condition in a cell, tissue, organ, patient or animal, comprising:

(a) contacting or administering a composition comprising an effective amount of at least one isolated mammalian anti-Dengue virus antibody of claim 1, with, or to, said cell, tissue, organ, patient or animal.

Claim 12. (withdrawn) A method according to Claim 11, wherein said effective amount is 0.001 to 50 mg/kilogram of said cells, tissue, organ, patient or animal.

Claim 13. (withdrawn) A method according to Claim 11, wherein said contacting or said administering is by at least one mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelical, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

Claim 14. (withdrawn) A method according to Claim 11, further comprising administering, prior, concurrently or after said (a) contacting or administering, at least one composition comprising an effective amount of at least one compound or protein selected from the group consisting of a detectable label or reporter, a Dengue virus replication antagonist, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, an antimicrobial, a corticosteroid, an erythropoietin, an antigen for immunization, an immunoglobulin, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an asthma medication, an inhaled steroid, an epinephrine or analog, a cytokine, and a cytokine antagonist.

Claim 15. (previously presented) A medical device, comprising at least one isolated mammalian anti-Dengue virus antibody having at least one variable region comprising SEQ ID NO: 4, wherein said device is suitable to contacting or administering said at least one anti-Dengue virus antibody by at least one mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

Claim 16. (previously presented) An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising a solution or a lyophilized form of at least one isolated mammalian anti-Dengue virus antibody having at least one variable region comprising SEQ ID NO: 4.

Claim 17. (previously presented) The article of manufacture of Claim 16, wherein said container is a component of a delivery device or system using a mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

Claim 18. (canceled)

Claim 19. (previously presented) An isolated mammalian anti-Dengue virus antibody having at least one variable region comprising SEQ ID NO: 4 produced by a method comprising providing a host cell or transgenic animal or transgenic plant or plant cell capable of expressing in recoverable amounts said antibody.

Claim 20. (previously presented) An isolated mammalian anti-Dengue virus antibody, comprising all of the light chain CDR amino acids sequences of SEQ ID NO: 4.

Claim 21. (original) A Dengue virus antibody according to Claim 20, wherein said antibody binds a Dengue virus NS protein.

Claim 22. (original) A Dengue virus antibody according to Claim 20, wherein said antibody binds at least one Dengue virus NS 1 protein.

Claims 23-27. (canceled)

Claim 28. (previously presented) A composition comprising at least one isolated mammalian anti-Dengue virus antibody having all of the light chain CDR amino acids sequences of SEQ ID NO: 4, and at least one pharmaceutically acceptable carrier or diluent.

Claim 29. (previously presented) A composition according to Claim 28, further comprising at least one composition comprising a therapeutically or prophylactically effective amount of at least one compound or protein selected from the group consisting of a detectable label or reporter, a Dengue virus replication antagonist, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, an antimicrobial, a corticosteroid, an erythropoietin, an antigen for immunization, an immunoglobulin, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an asthma medication, an inhaled steroid, an epinephrine or analog, a cytokine, and a cytokine antagonist.

Claim 30. (withdrawn) A method for diagnosing or treating a Dengue virus-related condition in a cell, tissue, organ, patient, animal or population of subjects comprising:

(a) contacting or administering a composition comprising an effective amount of at least one isolated mammalian anti-Dengue virus antibody of claim 20, with, or to, said cell, tissue, organ, patient or animal.

Claim 31. (withdrawn) A method according to Claim 30, wherein said effective amount is 0.001 to 50 mg/kilogram of said cells, tissue, organ, patient or animal.

Claim 32. (withdrawn) A method according to Claim 30, wherein said contacting or said administering is by at least one mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelical, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

Claim 33. (withdrawn) A method according to Claim 30, further comprising administering, prior, concurrently or after said (a) contacting or administering, at least one composition comprising a therapeutically or prophylactically effective amount of at least one compound or protein selected from the group consisting of a detectable label or reporter, a Dengue virus replication antagonist, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, an antimicrobial, a corticosteroid, an erythropoietin, an antigen for immunization, an immunoglobulin, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an asthma medication, an inhaled steroid, an epinephrine or analog, a cytokine, and a cytokine antagonist.

Claim 34. (previously presented) A medical device, comprising at least one isolated mammalian anti-Dengue virus antibody having all of the light chain CDR amino acids sequences of SEQ ID NO: 4, wherein said device is suitable to contacting or administering said at least one anti-Dengue virus antibody by at least one mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

Claim 35. (previously presented) An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising a solution or a lyophilized form of at least one isolated mammalian anti-Dengue virus antibody having all of the light chain CDR amino acids sequences of SEQ ID NO: 4.

Claim 36. (previously presented) The article of manufacture of Claim 35, wherein said container is a component of a delivery device or system which uses a mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

Claim 37. (canceled)

Claim 38. (previously presented) An isolated mammalian anti-Dengue virus antibody having all of the light chain CDR amino acid sequence of SEQ ID NO: 4 produced by a method comprising providing a host cell or transgenic animal or transgenic plant or plant cell capable of expressing in recoverable amounts nucleic acid molecules encoding said antibody.

Claim 39. (previously presented) An isolated mammalian anti-Dengue virus antibody, comprising at least one light chain CDR having the amino acid sequence of SEQ ID NO: 4.

Claim 40. (original) A Dengue virus antibody according to Claim 39, wherein said antibody binds a Dengue virus NS protein.

Claim 41. (original) A Dengue virus antibody according to Claim 39, wherein said antibody binds at least one Dengue virus NS 1 protein.

Claims 42-46. (canceled)

Claim 47. (previously presented) A composition comprising at least one isolated mammalian anti-Dengue virus antibody having at least one light chain CDR having the amino acid sequence of at least one of SEQ ID NO: 4, and at least one pharmaceutically acceptable carrier or diluent.

Claim 48. (previously presented) A composition according to Claim 47, further comprising at least one composition comprising a therapeutically or prophylactically effective amount of at least one compound or protein selected from the group consisting of a detectable label or reporter, a Dengue virus replication antagonist, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, an antimicrobial, a corticosteroid, an erythropoietin, an antigen for immunization, an immunoglobulin, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an asthma medication, an inhaled steroid, an epinephrine or analog, a cytokine, and a cytokine antagonist.

Claim 49. (withdrawn) A method for diagnosing or treating a Dengue virus related condition in a cell, tissue, organ, patient or animal, comprising:

(a) contacting or administering a composition comprising an effective amount of at least one isolated mammalian anti-Dengue virus antibody of claim 1, with, or to, said cell, tissue, organ, patient or animal.

Claim 50. (withdrawn) A method according to Claim 49, wherein said effective amount is 0.001 to 50 mg/kilogram of said cells, tissue, organ, patient or animal.

Claim 51. (withdrawn) A method according to Claim 49, wherein said contacting or said administering is by at least one mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

Claim 52. (withdrawn) A method according to Claim 49, further comprising administering, prior, concurrently or after said (a) contacting or administering, at least one composition comprising an effective amount of at least one compound or protein selected from the group consisting of a detectable label or reporter, a Dengue virus replication antagonist, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, an antimicrobial, a corticosteroid, an erythropoietin, an antigen for immunization, an immunoglobulin, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an asthma medication, an inhaled steroid, an epinephrine or analog, a cytokine, and a cytokine antagonist.

Claim 53. (previously presented) A medical device, comprising at least one isolated mammalian anti-Dengue virus antibody having at least one light chain CDR having the amino acid sequence of SEQ ID NO: 4, wherein said device is suitable to contacting or administering said at least one anti-Dengue virus antibody by at least one mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

Claim 54. (previously presented) An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising at least one isolated mammalian anti-Dengue virus antibody or nucleic acid molecule encoding said antibody, having at least one light chain CDR having the amino acid sequence of SEQ ID NO: 4.

Claim 55. (previously presented) The article of manufacture of Claim 54, wherein said container is a component of a delivery device or system that uses a mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

Claim 56. (canceled)

Claim 57. (previously presented) An isolated mammalian anti-Dengue virus antibody having at least one light chain CDR having the amino acid sequence of SEQ ID NO: 4 produced by a method comprising providing a host cell or transgenic animal or transgenic plant or plant cell capable of expressing a nucleic acid molecule encoding said antibody in recoverable amounts wherein said nucleic acid molecule comprises SEQ ID NO: 2.

Claim 58. (previously presented) An isolated mammalian anti-Dengue virus antibody that binds to the same region of a Dengue virus protein as an antibody comprising at least one light chain CDR having the amino acid sequence of SEQ ID NO: 4.

Claim 59. (original) A Dengue virus antibody according to Claim 58, wherein said antibody binds a Dengue virus NS protein.

Claim 60. (original) A Dengue virus antibody according to Claim 58, wherein said antibody substantially neutralizes at least one activity of at least one Dengue virus protein.

Claims 61-65. (canceled)

Claim 66. (previously presented) A composition comprising at least one isolated mammalian anti-Dengue virus antibody that binds to the same region of a Dengue virus protein as an antibody comprising at least one light chain CDR having the amino acid sequence of SEQ ID NO: 4, and at least one pharmaceutically acceptable carrier or diluent.

Claim 67. (previously presented) A composition according to Claim 66, further comprising at least one composition comprising a therapeutically or prophylactically effective amount of at least one compound or protein selected from the group consisting of a detectable label or reporter, a Dengue virus replication antagonist, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, an antimicrobial, a corticosteroid, an erythropoietin, an antigen for immunization, an immunoglobulin, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an asthma medication, an inhaled steroid, an epinephrine or analog, a cytokine, and a cytokine antagonist.

Claim 68. (withdrawn) A method for diagnosing or treating a Dengue virus related condition in a cell, tissue, organ, patient or animal, comprising:

(a) contacting or administering a composition comprising an effective amount of at least one isolated mammalian anti-Dengue virus antibody that binds to the same region of a Dengue virus protein as the antibody of claim 1, with, or to, said cell, tissue, organ, patient or animal.

Claim 69. (withdrawn) A method according to Claim 68, wherein said effective amount is 0.001 to 50 mg/kilogram of said cells, tissue, organ, patient or animal.

Claim 70. (withdrawn) A method according to Claim 68, wherein said contacting or said administering is by at least one mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

Claim 71. (withdrawn) A method according to Claim 68, further comprising administering, prior, concurrently or after said step (a) contacting or administering, at least one composition comprising an effective amount of at least one compound or protein selected from the group consisting of a detectable label or reporter, a Dengue virus replication antagonist, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, an antimicrobial, a corticosteroid, an erythropoietin, an antigen for immunization, an immunoglobulin, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an asthma medication, an inhaled steroid, an epinephrine or analog, a cytokine, and a cytokine antagonist.

Claim 72. (previously presented) A medical device, comprising at least one isolated mammalian anti-Dengue virus antibody or nucleic acid molecule encoding said antibody that binds to the same region of a Dengue virus protein as an antibody comprising at least one

light chain CDR having the amino acid sequence of SEQ ID NO: 4, wherein said device is suitable to contacting or administering said at least one anti-Dengue virus antibody by at least one mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

Claim 73. (previously presented) An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising at least one isolated mammalian anti-Dengue virus antibody or nucleic acid molecule encoding said antibody that binds to the same region of a Dengue virus protein as an antibody comprising at least one light chain CDR having the amino acid sequence of SEQ ID NO: 4.

Claim 74. (previously presented) The article of manufacture of Claim 73, wherein said container is a component of a delivery device or system which uses a mode of delivery selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

Claim 75. (canceled)

Claim 76. (currently amended) An isolated population of monoclonal mammalian anti-Dengue virus antibody that binds to the same region of a Dengue virus protein as an antibody comprising at least one light chain CDR having the amino acid sequence of SEQ ID NO: 4 produced by a method comprising providing a host cell or transgenic animal or transgenic plant or plant cell capable of expressing in recoverable amounts said antibody.

Claim 77. (previously presented) An isolated population of monoclonal mammalian anti-Dengue virus antibodies, comprising at least one human CDR, wherein said antibodies specifically bind at least one epitope comprising at least 1-3 amino acids, to the entire amino acid sequence of a Dengue virus NS protein.

Claim 78. (previously presented) The Dengue virus antibodies according to Claim 77, wherein said antibodies bind a Dengue virus NS1 protein.

Claim 79. (previously presented) The-Dengue virus antibodies according to Claim 77, wherein said antibodies substantially neutralize at least one activity of at least one Dengue virus NS protein.

Claims 80-84. (canceled)

Claim 85. (previously presented) A composition comprising an isolated population of monoclonal mammalian anti-Dengue virus antibodies having at least one human CDR, wherein said antibodies specifically bind at least one epitope comprising two or more amino acids of Dengue virus NS1 protein, and at least one pharmaceutically acceptable carrier or diluent.

Claim 86. (previously presented) A composition according to Claim 85, further comprising at least one composition comprising a therapeutically or prophylactically effective amount of at least one compound or protein selected from the group consisting of a detectable label or reporter, a Dengue virus replication antagonist, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, an antimicrobial, a corticosteroid, an erythropoietin, an antigen for immunization, an immunoglobulin, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an asthma medication, an inhaled steroid, an epinephrine or analog, a cytokine, and a cytokine antagonist.

Claim 87. (withdrawn) A method for diagnosing or treating a Dengue virus related condition in a cell, tissue, organ, patient or animal, comprising:

(a) contacting or administering a composition comprising an effective amount of at least one isolated mammalian anti-Dengue virus antibody of claim 77, with, or to, said cell, tissue, organ, patient or animal.

Claim 88. (withdrawn) A method according to Claim 87, wherein said effective amount is 0.001 to 50 mg/kilogram of said cells, tissue, organ, patient or animal.

Claim 89. (withdrawn) A method according to Claim 87, wherein said contacting or said administering is by at least one mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

Claim 90. (withdrawn) A method according to Claim 87, further comprising administering, prior, concurrently or after said (a) contacting or administering, at least one composition comprising an effective amount of at least one compound or protein selected from the group consisting of a detectable label or reporter, a Dengue virus replication antagonist, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, an antimicrobial, a corticosteroid, an erythropoietin, an antigen for immunization, an immunoglobulin, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an asthma medication, an inhaled steroid, an epinephrine or analog, a cytokine, and a cytokine antagonist.

Claim 91. (previously presented) A medical device, comprising at least one isolated mammalian anti-Dengue virus antibody or a nucleic acid molecule encoding said antibody, having at least one human CDR, wherein said antibody specifically binds at least one epitope comprising at least 1-3 amino acids, to the entire amino acid sequence of a Dengue virus NS protein, wherein said device is suitable to contacting or administering said anti-Dengue virus antibody by at least one mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal,

intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

Claim 92. (original) An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising at least one isolated mammalian anti-Dengue virus antibody or a nucleic acid molecule encoding said antibody, having at least one human CDR, wherein said antibody specifically binds at least one epitope comprising two or more amino acids of Dengue virus NS1 protein.

Claim 93. (previously presented) The article of manufacture of Claim 92, wherein said container is a component of a delivery device or system which uses a mode selected from the group consisting of parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal.

Claim 94. (canceled)

Claim 95. (previously presented) A population of monoclonal mammalian anti-Dengue virus antibodies having at least one human CDR wherein said antibody specifically binds at least one epitope comprising two or more amino acids of Dengue virus NS1 protein, produced by a method comprising providing a host cell or transgenic animal or transgenic plant or plant cell capable of expressing in recoverable amounts said antibodies.